Vaccines may be more effective against Brazilian variant than previously thought, study suggests
South African variant remains most worrying
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Vaccines currently in use in the UK may be more effective against the Brazilian variant of coronavirus than previously thought, a new study suggests.
The research, which has not yet been peer-reviewed, found the Oxford/AstraZeneca and Pfizer/BioNTRech vaccines may not need to be modified to combat the spread of the P1 Brazil strain.
Scientists from Oxford University measured the level of antibodies that can neutralise coronavirus variants circulating in South Africa, Brazil and elsewhere.
They found that although vaccines do not work as well against the variants as against the original strain of coronavirus, the P1 Brazilian variant may be less resistant to vaccine-induced antibodies than first feared.
“This study extends our understanding the role of changes in the spike protein in escape from the human immune response, measured as neutralising antibody levels,” said Professor Gavin Screaton, lead scientist on the study.
“The results suggest that P1 might be less resistant to vaccine and convalescent immune responses than B1351 (South Africa), and similar to B117 (Kent).”
Read more:
The study used blood samples from people who have natural antibodies generated from a Covid-19 infection and those whose antibodies were induced by the Oxford or Pfizer vaccines.
It found a nearly three-fold reduction in the level of virus neutralisation by the antibodies generated by the Oxford and Pfizer vaccines for the Kent and Brazil variants when compared to the original strain.
The vaccines struggled harder with the South African variant, showing a nine-fold and 7.6-fold reduction respectively in the level of virus neutralisation involving the variant.
The study suggests the South African variant remains the most worrying, indicating it should be the focus for manufacturers making new vaccines.
Professor Andrew Pollard, chief investigator on the Oxford University vaccine trial, said: “These further efforts to investigate the relationship between changes in the virus and human immunity provide new insights that help us be prepared to respond to further challenges to our health from the pandemic virus, if we need to do so.”
Surge testing has been employed to help prevent the spread of the Brazilian and South African variants after cases were identified in the UK.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments